COB Columbia Laboratories

Columbia Laboratories Appoints George W. Creasy, M.D. to Vice President, Clinical Research, and Paul B. Schwartz to Executive Director, Licensing & Business Development LIVINGSTON, N.J., Nov. 18 /PRNewswire-FirstCall/ -- Columbia Laboratories, Inc. today announced the appointments of George W. Creasy, M.D., to Vice President, Clinical Research, and Paul B. Schwartz to Executive Director, Licensing & Business Development. Dr. Creasy will have overall responsibility for Columbia's clinical research programs and will oversee medical affairs for marketed products. "George will contribute valuable experience to our recently announced PROTERM (PROgesterone Gel for Reducing PreTERM Labor and Delivery) Study designed to investigate the prevention of preterm delivery in pregnant women who are at increased risk for preterm birth," stated Fred Wilkinson, Columbia's president and CEO. "His many years of clinical research experience in women's health care will enhance our ability to advance our focused clinical programs." Mr. Schwartz will be responsible for identifying products and technology opportunities for both in- and out-licensing on a worldwide basis. "Licensing is expected to play an important role in the future of Columbia Laboratories following the launch of Striant(TM) (testosterone buccal system), our testosterone product for men, by providing additions to our product portfolio and partnerships for our key research projects," stated Wilkinson. "Paul's strong track record of success within our target markets can provide an immediate impact on projects currently under negotiation, as well as on execution of our overall strategy." Dr. Creasy joins Columbia Laboratories with solid experience in medicine and clinical drug development. Before joining the Company, he was responsible for clinical development and management of reproductive health products in his more than 16 years with Johnson & Johnson. Dr. Creasy is a graduate of the Pennsylvania State University School of Medicine, and is a trained Obstetrician and Gynecologist. He was a faculty member of Penn State's Hershey Medical Center prior to starting his pharmaceutical career. Mr. Schwartz joins Columbia Laboratories following a career of multi-disciplined experience in the pharmaceutical industry. Prior to joining the Company, he served in various positions with Pharmacia Corporation and its heritage companies, Pharmacia & Upjohn and The Upjohn Company, including nearly 19 years in licensing-related activities, most recently in women's health and urology. Mr. Schwartz is a graduate of the University of Minnesota College of Pharmacy, as well as the Business Management Program at Kalamazoo College. About Columbia Laboratories Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company dedicated to the development and commercialization of women's health care and endocrinology products, including those intended to treat infertility, dysmenorrhea, endometriosis and hormonal deficiencies. Columbia has introduced Striant(TM) for treatment of hypogonadism in men. The Company is also developing a buccal delivery system for peptides. Columbia's products primarily utilize the Company's patented Bioadhesive Delivery System (BDS) technology. For more information, please visit http://www.columbialabs.com/. This press release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Those statements include statements regarding the intent, belief or current expectations of the company and its management team. Such statements include statements concerning implementation of the PROTERM Study, and in- and out- licensing of products. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. Such risks and uncertainties include, among other things, the successful marketing of existing products, including Striant(TM) (testosterone buccal system), Prochieve(R) 8% (progesterone gel), Prochieve(R) 4% (progesterone gel), RepHresh(R) Vaginal Gel, and Advantage-S(R) Contraceptive Gel; timely and successful development of new products; timely and successful completion of clinical studies; success in obtaining acceptance and approval of new products by the FDA and international regulatory agencies; and competitive economic and regulatory factors in the pharmaceutical and health care industry; general economic conditions; and other risks and uncertainties that may be detailed, from time- to-time, in Columbia's reports filed with the Securities and Exchange Commission. DATASOURCE: Columbia Laboratories, Inc. CONTACT: Jim Apostolakis, Vice Chairman, +1-212-588-1900, or David Weinberg, Chief Financial Officer, +1-973-994-3999, both of Columbia Laboratories, Inc.; or Investor Relations - Ritu Baral of The Trout Group, +1-212-477-9007, ext 25, for Columbia Laboratories, Inc. Web site: http://www.columbialabs.com/

Copyright